It is a known prostate cancer stem cell marker (46) that has been nominated as a potential therapeutic target (47) and has been shown to play a role in chemo- and radiotherapy response and resistance in prostate cancer (48, 49), nominating CD44 as a valuable marker and potential therapeutic target, requiring further in-depth investigations. This evidence concerns the gene CD44 and prostate carcinoma.